Theravance Biopharma (TBPH) Projected to Post Earnings on Wednesday

Theravance Biopharma (NASDAQ:TBPH) is anticipated to announce its earnings results after the market closes on Wednesday, February 26th. Analysts expect the company to announce earnings of ($0.05) per share and revenue of $29.90 million for the quarter. Investors that wish to register for the company’s conference call can do so using this link.

Theravance Biopharma Stock Performance

NASDAQ:TBPH opened at $8.86 on Tuesday. The company has a market capitalization of $435.68 million, a PE ratio of -8.77 and a beta of 0.21. The company has a 50 day simple moving average of $9.38 and a two-hundred day simple moving average of $8.90. Theravance Biopharma has a fifty-two week low of $7.44 and a fifty-two week high of $10.90.

Insider Transactions at Theravance Biopharma

In related news, SVP Rhonda Farnum sold 4,000 shares of the stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $9.00, for a total value of $36,000.00. Following the transaction, the senior vice president now directly owns 309,565 shares in the company, valued at $2,786,085. This trade represents a 1.28 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 6.90% of the company’s stock.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.